Ser375
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser375  -  MOR-1 (mouse)

Site Information
QNtREHPstANtVDR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447784

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 , 3 ) , immunoprecipitation ( 6 ) , mass spectrometry ( 4 , 6 , 11 ) , mutation of modification site ( 3 , 4 , 5 , 6 , 8 , 10 , 11 , 13 ) , phospho-antibody ( 1 , 2 , 3 , 6 , 7 , 8 , 9 , 10 , 12 , 13 ) , western blotting ( 2 , 3 , 6 , 7 , 8 , 9 , 10 , 12 , 13 )
Disease tissue studied:
pituitary cancer ( 13 )
Relevant cell line - cell type - tissue:
'brain, striatum' ( 13 ) , 'neuron, striatal'-brain ( 8 ) , 293 (epithelial) ( 2 , 3 , 7 , 8 , 9 , 10 , 11 , 13 ) , AtT20 (pituitary cell) ( 13 ) , brain ( 1 , 4 , 6 , 9 ) , brain [MOR-1 (mouse), homozygous knockout] ( 7 ) , neuron ( 12 ) , neuron-brain ( 5 ) , spinal cord ( 1 )

Upstream Regulation
Regulatory protein:
GRK2 (human) ( 9 ) , GRK3 (human) ( 9 ) , GRK5 (human) ( 9 ) , GRK6 (human) ( 9 ) , MOR-1 (mouse) ( 7 ) , RGS14 (mouse) ( 12 )
Putative in vivo kinases:
GRK2 (human) ( 2 , 3 , 8 , 9 ) , GRK3 (human) ( 3 , 6 , 8 , 9 ) , GRK5 (human) ( 6 , 9 )
Putative upstream phosphatases:
PPP1CA (human) ( 9 )
Treatments:
SR-17018 ( 2 ) , acid wash ( 10 ) , calyculin_A ( 9 ) , Cmpd101 ( 2 , 3 ) , ConA ( 10 ) , DAMGO ( 2 , 3 , 7 , 8 , 9 , 10 , 12 ) , etonitazene ( 4 , 6 , 7 , 8 , 9 , 10 ) , fentanyl ( 1 , 2 , 4 , 6 , 8 , 13 ) , methadone ( 2 ) , morphine ( 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ) , naloxone ( 1 , 2 , 10 , 13 ) , NKH_477 ( 10 ) , okadaic_acid ( 9 ) , oliceridine ( 2 ) , oxycodone ( 2 ) , painful stimulus ( 13 ) , phorbol_ester ( 7 , 10 ) , PZM21 ( 2 ) , Ro-32-0432 ( 7 ) , siRNA ( 3 , 9 )

Downstream Regulation
Effects of modification on MOR-1:
molecular association, regulation ( 2 , 3 ) , phosphorylation ( 3 , 6 , 8 , 10 ) , receptor desensitization, induced ( 3 , 10 ) , receptor internalization, induced ( 2 , 8 , 9 , 11 )
Effects of modification on biological processes:
endocytosis, induced ( 3 , 9 , 11 ) , signaling pathway regulation ( 2 , 6 )
Induce interaction with:
ARRB2 (human) ( 2 , 3 )

References 

1

Fritzwanker S, et al. (2023) In situ visualization of opioid and cannabinoid drug effects using phosphosite-specific GPCR antibodies. Commun Biol 6, 419
37061609   Curated Info

2

Gillis A, et al. (2020) Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal 13
32234959   Curated Info

3

Miess E, et al. (2018) Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization. Sci Signal 11
30018083   Curated Info

4

Moulédous L, et al. (2015) Phosphoproteomic analysis of the mouse brain mu-opioid (MOP) receptor. FEBS Lett 589, 2401-8
26226422   Curated Info

5

Bowman SL, et al. (2015) Cell-autonomous regulation of Mu-opioid receptor recycling by substance P. Cell Rep 10, 1925-36
25801029   Curated Info

6

Glück L, et al. (2014) Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biol Psychiatry 76, 767-74
24629717   Curated Info

7

Illing S, Mann A, Schulz S (2014) Heterologous regulation of agonist-independent μ-opioid receptor phosphorylation by protein kinase C. Br J Pharmacol 171, 1330-40
24308893   Curated Info

8

Just S, et al. (2013) Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol Pharmacol 83, 633-9
23239825   Curated Info

9

Doll C, et al. (2012) Deciphering µ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br J Pharmacol 167, 1259-70
22725608   Curated Info

10

Doll C, et al. (2011) Agonist-selective patterns of µ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol 164, 298-307
21449911   Curated Info

11

Lau EK, et al. (2011) Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection. Sci Signal 4, ra52
21868358   Curated Info

12

Rodríguez-Muñoz M, et al. (2007) RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons. Cell Signal 19, 2558-71
17825524   Curated Info

13

Petraschka M, et al. (2007) The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation. Neuroscience 146, 1795-807
17467916   Curated Info

PhosphoSitePlus® is a registered trademark of Cell Signaling Technology.
Use of PSP data is subject to a formal license agreement. Learn more

©2003-2025 Cell Signaling Technology, Inc.